Cronos Group Inc. (CRON) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cronos Group Inc. (CRON:NASDAQ), powered by AI.

Current Price
$2.53
P/E Ratio
23.5
Market Cap
967M
Sector
Healthcare
What is the Cronos Group Inc. stock price forecast?

Cronos Group Inc. is currently trading at $2.53. View real-time AI analysis on Alpha Lenz.

What is Cronos Group Inc. insider trading activity?

View the latest insider trading data for Cronos Group Inc. on Alpha Lenz.

What is Cronos Group Inc.'s P/E ratio?

Cronos Group Inc.'s P/E ratio is 23.5.

Cronos Group Inc.

$2.53
NASDAQCRON
Ask about Cronos Group Inc.'s future dividend policy...
Alpha Chat Insight

Cronos Group Inc. trades at a P/E of 23.5 (fair value) with modest ROE of 3.8%. 3Y revenue CAGR of 22.1% highlights clear growth momentum.

Ask for details

Company Overview

Cronos Group Inc. is a vertically integrated cannabis company that engages in the cultivation, manufacturing, and distribution of cannabis and related products. Its primary focus is on producing and selling cannabis flower, oils, and derivative products for recreational and medicinal purposes. The company's operations span across different international markets, leveraging strategic partnerships to expand its footprint and influence in the rapidly evolving cannabis industry. Cronos Group is known for investing in research and development to advance cannabinoid innovation and enhance its product offerings. It not only addresses consumer needs through various brands but also aims to comply with stringent regulatory frameworks in the regions it serves. As an active participant in the cannabis sector, Cronos Group plays a crucial role in shaping industry standards and responding to changing market dynamics. With an emphasis on sustainability and corporate responsibility, Cronos contributes to the broader acceptance and understanding of cannabis as a major component of the health and wellness market.

CEOMr. Michael Ryan Gorenstein J.D.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees459

Company Statistics

(FY 2024)

Profile

Market Cap$966.61M
Revenue$117.61M
Shares Out0.00
Employees459

Margins

Gross21.42%
EBITDA-50.88%
Operating-50.63%
Pre-Tax31.11%
Net34.03%

Valuation

P/E23.53
P/B0.91
EV/Sales8.22
EV/EBITDA-2.62
P/FCF169.91

Growth (CAGR)

Rev 3Yr22.13%
Rev 5Yr48.40%
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5Yr-45.09%

Returns

ROA3.47%
ROE3.80%
ROIC-5.16%

Financial Health

Cash & Cash Equivalents$858.80M
Net Debt$-803.48M
Debt/Equity4.98%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Cronos Group Inc. (Healthcare) Stock Forecast & Analysis $2.53 | Alpha Lenz